Market Overview

UPDATE: Goldman Sachs Initiates Genomic Health at Neutral on Limited Upside

Related GHDX
Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer
Oncotype DX Predicts Outcomes In Prostate Cancer Patients, Significantly Changes Treatment Recommendations

Goldman Sachs initiated coverage on Genomic Health (NASDAQ: GHDX) with a Neutral rating and a $36 price target.

Goldman Sachs commented, "Our thesis is based on (1) growth potential from new product cycles offset by (2) underappreciated market development costs and (3) mounting competition and an uncertain regulatory environment. How we are different: Our proprietary analysis of GHDX's new products and the regulatory landscape suggests these new tests may improve on the standard of care but face material uncertainties that are not yet fully appreciated by the Street."

Genomic Health closed at $33.77 on Wednesday.

Latest Ratings for GHDX

DateFirmActionFromTo
Nov 2014Credit SuisseMaintainsNeutral
Nov 2014Bank of AmericaMaintainsUnderperform
Nov 2014Canaccord GenuityMaintainsHold

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GHDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters